Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, novembre 17
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Xenon Pharmaceuticals Inc
XENE
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$38.42
-0.84
-2.14%
Ult. Agg.: Nov 17, 11:56 AM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Xenon Pharmaceuticals Financials
Xenon Pharmaceuticals (XENE) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Xenon Pharmaceuticals Q3 EPS $(1.11) Beats $(1.13) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.13) by 1.77 percent. This is a 3.48 percent increase over losses of $(1.15) per share
Benzinga Newsdesk
PRO
Xenon Pharmaceuticals Q2 EPS $(1.11) Beats $(1.15) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.15) by 2.63 percent. This is a 3.74 percent decrease over losses of $(1.07) per share
Benzinga Newsdesk
PRO
Xenon Pharmaceuticals Q1 EPS $(1.17) Beats $(1.20) Estimate, Cash, Cash Equivalents And Marketable Securities Of $1.3B Extends Cash Runway Into 2029
Benzinga Newsdesk
PRO
Xenon Pharmaceuticals Q4 EPS $(1.31) Misses $(1.19) Estimate
Benzinga Newsdesk
PRO
Xenon Pharmaceuticals Q3 EPS $(1.15), Inline. Cash And Equivalents $555.3M
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(1.15) per share which met the analyst consensus estimate. This is a 41.98 percent decrease over losses of $(0.81) per share from the same period last
Benzinga Newsdesk
Earnings Scheduled For November 3, 2025
Benzinga Insights